Shots:

• Polpharma reported that its JV with Santo Holding- Bioeq has concluded a commercial partnership with Teva for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis) in the EU- Canada- Israel- and New Zealand
• The agreement complements an existing agreement concluded with Coherus for the commercialization of the biosimilar in the US
• FYB201 was originally licensed from Formycon and subsequently developed by Bioeq and has demonstrated efficacy in patients with nAMD is comparable to that of reference product- Lucentis

| Ref: Businesswire| Image: Seeking Alpha